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Experience with the Novacor left ventricular 
system as a bridge to cardiac transplantation, 
including the new wearable system 
assist 
The three components of the Novacor left ventricular assist system, compact controller, battery, and 
back-up battery, have been miniaturized in the development of he wearable system. Therefore patients 
can be fully mobilized receiving mechanical circulatory support while awaiting heart transplantation. 
Between February 1992 and April 1994 a total of eight patients with decompensated heart failure (6 
dilated cardiomyopathy, I acute myocarditis, I ischemic ardiomyopathy) were treated with the Novacor 
left ventricular assist system. In the most recent four cases the wearable system (N100P) was used. 
Patients' ages ranged from 17 to 49 years. In five patients evere failure of the right side of the heart was 
present at the time of implantation. Hemodynamic stabilization was achieved in all patients during the 
2 to 122 days (mean 30.8 - 42.5 days) of support. The following parameters were measured on average 
before and 24 hours after implantation of the left ventricular assist system: mean arterial pressure 70 - 
11 versus 87 +- 13 mm Hg (p < 0.05), cardiac index 1.71 _ 0.42 versus 3.23 - 0.74 L/min/m 2 (p < 0.05), 
pulmonary capillary wedge pressure 27.1 - 4.4 versus 9.9 - 5.2 mm Hg (p < 0.01), mean pulmonary 
pressure 41 - 9 versus 27 - 6 mm Hg (p < 0.05), and right ventricular ejection fraction 16.7% - 10.3% 
versus 22.0% - 11.6% (not significant). Patients who received the wearable system were capable of 
managing their own power supply during the bridging period and were able to walk to the hospital park 
and shopping area. One patient had a serious pulmonary infection, which was treated successfully, and 
two patients had a cerebrovascular accident, which resolved in one and resulted in a minor residual 
deficit in the other. All eight patients received a heart transplant. One patient died early after 
transplantation a d seven patients are alive and well. In summary, the wearable Novacor left ventricular 
assist system provides major advantages regarding quality of life of patients during mechanical 
circulatory support. However, there is a remaining risk of thromboembolism despite anticoagulation 
therapy. (J THORAC CARDIOVASC SURG 1995;109:74-80) 
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Card iac  transplantation has become an accepted 
method in clinical therapy for end-stage heart dis- 
ease. However, the shortage of donors is responsible 
for a high percentage of patients dying while await- 
ing heart transplantation. Within the past decade 
electrically powered ventricular assist devices I and 
pneumatically driven artificial hearts 2 have been 
used in clinical programs to rescue critically ill 
cardiac transplant candidates. Because the average 
waiting time for a donor heart increased uring the 
past few years this situation has resulted in pro- 
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Fig. 1. Wearable Novacor LVAS. 
longed periods of mechanical circulatory support. 
However, the incidence of thromboembol ism re- 
mains a major threat in patients who receive long-term 
support. Anticoagulation protocols and changes in 
device design are important factors for the outcome of 
such patients) Since 1993 the large external console of 
the Novacor left ventricular assist system (LVAS) has 
been miniaturized: the result is a system that can be 
worn on a belt and that allows a higher degree of 
mobility and quality of life to patients during the 
waiting period. 
Material and methods 
Assist device. The Novacor NIO0 LVAS (Novacor Di- 
vision, Baxter Healthcare Corp., Oakland, Calif.), is an 
electromagnetically actuated implantable pump that con- 
sists of a seamless one-piece smooth polyurethane sac that 
is bonded to symmetrically opposed dual pusher-plates. 
The housing is a lightweight shell that incorporates bovine 
pericardial valve fittings and an energy converter. The 
implanted pump unit is connected to the extracorporeal 
control console or wearable controller via a percutaneous 
lead (Fig. 1). Inflow and outflow Dacron fabric grafts, 
which both perforate the diaphragm, connect the pump to 
the left ventricular apex and to the ascending aorta. The 
maximal stroke volume of 70 ml can provide a pump 
output up to 10 L/min. With operation in synchronous 
counterpulsation cardiac rates of up to 240 beats/rain can 
be achieved. 4 
The external console used for the first four patients 
weighed approximately 150kg and usually required an 
engineer or other assistant to help the patient move about. 
The new wearable controller and external batteries are 
substantially smaller and weigh approximately 3 kg. They 
can be either worn on a belt or carried in a shoulder bag 
for much easier mobility. Untethered operation is 
achieved when two direct-current power sources are con- 
nected (Fig. 1). With batteries, the patient is fully mobile 
up to 6 hours and independent of alternating-current 
power or monitor. This is a major step in getting the 
patients fully ambulatory to improve quality of life during 
mechanical circulatory support. 
Patients. Between February 1992 and April 1994 the 
Novacor LVAS was implanted in eight patients as a bridge 
to cardiac transplantation. The wearable system was used 
for the most recent four patients. Dilated cardiomyopathy 
in six patients, end-stage ischemic heart disease in one 
patient, and acute myocarditis in one patient were the 
underlying diseases when the patients were evaluated as 
heart ransplant candidates. Before Novacor implantation 
two patients were supported by intraaortic balloon coun- 
terpulsation. The mean patient age was 31.6 _+ 12.9 years 
(range 16 to 49 years). The average body surface area was 
1.83 -+ 0.10 m z and ranged from 1.72 to 1.98 m 2. 
The clinical status and hemodynamics of all patients 
were deteriorating despite inotropic or vasodilator sup- 
port, or both therapies. Preoperative patient data are 
given in Table I. Cardiac output and parameters of 
function of the right side of the heart were evaluated by 
means of a rapid-response thermodilution catheter. In five 
of the eight patients right ventricular ejection fraction was 
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Table I. Preoperative patient data 
Body Central venous 
surface Cardiac index pressure Preoperative 
Patient No. Age (y r )  Diagnosis area (m 2) (L/minim 2) (ram Hg) inotropic agents 
1 17 DCM 1.81 1.0 34 A, D, Db 
2 16 AM 1.75 2.0 7 A, D, Db, E 
3 32 DCM 1.87 1.3 28 D, Db, NA 
4 49 DCM 1.72 1.5 14 D, Db, IABP 
5 48 IHD 1.98 2.0 5 D, IABP 
6 26 DCM 1.81 2.2 20 D, Db 
7 25 DCM 1.75 1.8 20 A, NA, D, Db, E 
8 40 DCM 1.95 2.0 17 D, E 
Mean -+ sD 31.6 _+ 12.9 1.83 -+ 0.10 1.7 _+ 0.4 18 +_ 10 
DCM, Dilated cardiomyopathy; A, adrenaline; D, dopamine; Db, dobutamine; AM, acute myocarditic; E, enoximone; NA, noradrenaline; IABP, intraaortic 
balloon pump, IHD, ischemic heart disease; SD, standard deviation. 
only 4% and in the others the value was 13%, 15%, and 
16%, respectively. Renal function was reduced with oli- 
guria or anuria and a mean serum creatinine level of 
1.50 _+ 0.54 mg/dl. Mean total bilirubin level was 2.11 --- 
1.51 mg/dl and the mean value of aspartate aminotrans- 
ferase was 198 _+ 246 mg/dl (range 70 to 660 mg/dl) before 
Novacor LVAS implantation. 
Surgical technique. The implantation technique based 
on suggestions by Oyer and associates 5 was modified in 
various steps to minimize bleeding and other procedure- 
related complications. The heart was exposed through a 
median sternotomy. In all cases the original outflow graft 
(Dacron fabric, not preclotted) of the pump system was 
replaced by a sealed vascular graft (Vascutek graft, Vas- 
cutek, Renfrewshire, Scotland), and the inflow conduit 
was preclotted with fibrin glue (Tissucol fibrin glue, 
Immuno, Vienna, Austria). A pocket was then prepared in 
the left upper quadrant of the abdominal wall, anterior to 
the posterior ectus muscle sheath. Cardiopulmonary b - 
pass was instituted by cannulating the ascending aorta for 
arterial perfusion and the superior and inferior venae 
cavae for venous return. A vent was placed inside the left 
ventricular cavity via the right upper pulmonary vein. 
After the outflow graft was anastomosed to the ascending 
aorta, cardiopulmonary b pass was started for insertion of 
the left ventricular apical conduit. The aorta was cross- 
clamped and the heart arrested with use of either crystal- 
loid (Bretschneider solution) or cold blood cardioplegia 
according to Buckberg. 6 After ventriculotomy at the left 
ventricular apex was completed, the inflow conduit was 
replaced and the pump and the grafts were carefully 
evacuated of air and continuous pumping begun. To 
prevent adhesions the outflow graft was covered with a 
sheath of polytetrafluoroethylene.* The abdominal facia 
was extended by a resorbable mesh (Vicryl mesh, Ethicon, 
Inc., Somerville, N.J.) in six patients to provide suitable 
space for accommodation f the pump. 
Anticoagulation protocol. The perioperative anticoag- 
ulation treatment consisted of 2 million units of aprotinin 
and regular heparinization (300 IU/kg body weight) for 
cardiopulmonary bypass. Systemic heparinization was 
* Gore-Tex Surgical Membrane. Gore-Tex is a registered trade- 
mark of W. L. Gore & Associates, Putzbrunn, Germany. 
fully antagonized with protamine sulfate at the end of 
cardiopulmonary b pass. 
In the postoperative phase intravenous administration 
of heparin was started when the activated partial throm- 
boplastin time (aPTf) was less than 50 seconds or the 
activated coagulation time was less than 140 seconds. 
Heparinization was considered sufficient if the aPTT 
ranged between 60 and 80 seconds. When patients were 
mobilized, the anticoagulation treatment was changed to 
oral phenprocoumon (Marcumar), maintaining the pro- 
thrombin time level at an international normalized ratio 
of 3.0 to 4.5. 7 Antithrombin 1II was substituted when 
levels fell below 80%. The protocol for postoperative 
anticoagulation was changed after a thromboembolic 
event in patient 7. It now includes heparin intravenously 
and then subcutaneously, acetylsalicylic acid 100 mg/d, 
and dipyridamole 75 mg/8 hourly. 
After operation the following tests were frequently used 
to monitor anticoagulation therapy: aPTT, prothrombin 
time, platelet count, fibrinogen, activated coagulation 
time, antithrombin III, a-2-haptoglobin, and hemo- 
pexin-S. For evaluation of platelet function a specific test, 
"bleeding time ex vivo," according to Kratzer and Born 8 
was applied (Thrombostat 4000, Baxter, Unterschleiss- 
heim, Germany). 
Statistics. Data are given as mean values ___ standard 
deviation. The X 2 test was used to calculate significant 
differences between groups; Fisher's exact est was used in 
small sample sizes. Yates' correction for continuity was 
done. A p value of 0.05 was taken as the level of 
significance. 
Results 
Hemodynamic data. The hemodynamic situation 
was significantly improved after implantation of the 
LVAS (Figs. 2 and 3). Mean arterial pressure in- 
creased from 70 _+ 11 mm Hg to 87 + 13 mm Hg 
(p < 0.05). Mean cardiac index, 1.71 -+ 0.42 
L/min/m 2 before Novacor LVAS implantation, rose 
to 3.23 ___ 0.74 L/min/m 2 24 hours after the start of 
mechanical circulatory support (p < 0.01). Average 
pulmonary capillary wedge pressure was 27.1 _+ 4.4 
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Fig. 2. Function of the left side of the heart in patients before and 24 hours after implantation ofNovacor 
LVAS. PCWP, Pulmonary capillary wedge pressure (mm Hg); MAP, mean arterial pressure (mm Hg); CI, 
cardiac index (L/min/m2); asterisk, p < 0.05. 
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Fig. 3. Function of the right side of the heart in patients before and 24 hours after implantation of 
Novacor LVAS. CVP, Central venous pressure (ram Hg); MPAP, mean pulmonary artery pressure (mm 
Hg); RVEF, right ventricular ejection fraction (%); asterisk, p < 0.05. 
mm Hg (range 22 to 34 mm Hg) before operation 
and decreased to 9.9 + 5.2 mm Hg (range 4 to 13 
mm Hg after operation (p < 0.05). 
Central venous pressure was 18.1 _+ 9.8 mm Hg 
on average before Novacor LVAS implantation and 
15.0 + 6.3 mm Hg during left ventricular support 
(not significant). Mean pulmonary artery pressure 
decreased from 41 + 9 mm Hg before operation to 
27 + 6 mm Hg after operation (p < 0.05). Calcula- 
tion of right ventricular ejection fraction could be 
done in seven patients: the mean value was 16.7% + 
10.3% (range 4% to 30%) before operation and 
increased uring mechanical left ventricular support 
to 22.0% _+ 11.6% (range 10% to 45%). However, 
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Fig. 4. Time course of hepatic and renal function of three patients who received long-term support with 
the Novacor LVAS. Parameters normalized on average after 20days of mechanical circulatory support. 
SGOT, aspartate aminotransferase; SGPT, alanine aminotransferase. 
this increase was not statistically significant. There 
was no significant difference in heart rate before 
and after operation: average 120 _+ 17 beats/rain and 
117 +_ 7 beats/rain, respectively. Mean values of all 
the parameters mentioned id not differ significantly 
when evaluated immediately before heart ransplan- 
tation. In patients who received LVAS support for 
more than 20 days, hepatic and renal function was 
improved before transplantation (Fig. 4). 
Recovery period. Three patients were kept on the 
regular ward after initial recovery in the intensive 
care unit. Patients were mobilized and were eventu- 
ally able to walk to the hospital park and to the 
shopping area. Trips to sightseeing areas in town 
were arranged together with the LVAS operators. 
A program for physical activities was initiated in 
cooperation with the physiotherapists. A daily "ac- 
tivities schedule" was arranged for each patient o 
provide psychologic support. This included physical 
activities, games (such as chess), and visits from 
relatives and medical students involved in the clini- 
cal study. 
Complications. Only one patient acquired a doc- 
umented serious pulmonary infection caused by 
Legionella bozemanii. He was treated successfully 
with erythromycin, ciprofloxacin, and fluconazole. 
A tendency of prolonged bleeding was observed 
in most of the patients. Surgical intervention was 
necessary in five patients; three had a cardiac tam- 
ponade within the first postoperative week and a 
rethoracotomy because of cardiac tamponade was 
done in two patients who received long-term sup- 
port. One patient underwent revision of the subcu- 
taneous area of the abdominal pocket because of a 
hematoma. 
Two patients who received long-term support had 
an embolic accident during left ventricular circula- 
tory support (Table II). These occurred on days 40 
(severe impairment of visual function) and 31 
(hemiparesis) of support, respectively. The possible 
source of this thromboembolism was found after 
explanation of the pump. Various amounts of 
thrombotic material were found on the proximal 
and distal sides of the inflow pericardial valve pros- 
theses (Fig. 5). The neurologic lesions resolved 
completely in one patient and only a minor neuro- 
logic deficit remained at the time of transplant in the 
other patient. 
Outcome. Five patients received short-term (<7 
days) and three patients long-term (->50 days) sup- 
port (Table II). Orthotopic heart transplantation 
was done in all eight patients. One patient died 2 
days after transplantation because of unspecific do- 
nor heart failure. The remaining seven patients are 
alive and well 1 to 25 months after heart transplan- 
tation. Four patients returned to work, one patient 
was already retired before the operations, one pa- 
tient is currently in rehabilitation, and one patient is 
in the hospital awaiting discharge 2 weeks after 
heart transplantation. 
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Table II. Complications and outcome 
Days of 
Patient L VAS Time since 
No. Complications support Outcome HTx (mos) 
1 CT day 1, RF, sternum open 3 HTx, alive, working 25 
2 RF, sternum open 2 HTx, died day 2 postop. - -  
3 CT day 2 5 HTx, alive, working 21 
4 CT day 3 7 HTx, alive, retired 18 
5 CT day 8, CVA day 40 52 HTx, alive, working 12 
6 None 5 HTx, alive, working 11 
7 CVA day 31, WR, lung infection 50 HTx, alive, rehabilitation 6 
8 CT days 15 and 22, RF, WR 122 HTx, alive, in hospital 1 
CT, Cardiac tamponade; HTx, heart ransplantation; RF, renal failure; CVA, cerebrovascular accident; WR, wound revision. 
Discussion 
This series of patients who underwent bridge to 
cardiac transplantation with the Novacor LVAS 
shows that mechanical circulatory support can be 
done with low mortality while providing significant 
hemodynamic improvement and physical rehabilita- 
tion. Hemodynamic data showed that parameters of
function of the left side of the heart can be improved 
significantly within 24 hours of the institution of 
circulatory support. In the majority of patients pump 
operation in synchronous counterpulsation could be 
achieved immediately after Novacor LVAS implan- 
tation and provided apump output ranging between 
4.5 and 8.0 L/min. As a result impaired renal 
function improved rapidly (within hours or within 
the first 2 postoperative days). Continuous hemofil- 
tration was necessary only in two patients in the 
early postoperative phase. Pennington and associ- 
ates 9 reported in a series of 44 cases that used 
different methods of circulatory support hat there is 
excellent functional recovery and survival of such 
patients. 
Despite severe impairment, function of the right 
side of the heart improved significantly during iso- 
lated left ventricular support. Implantation of a right 
ventricular assist device was not indicated. In a 
clinical study Kormos and colleagues 1° demon- 
strated an improvement of the function of the right 
side of the heart in most patients after implantation 
of the Novacor system. 
In our center the Novacor LVAS has proved to be 
a highly reliable system for assisting the failing 
heart. No technical faults have been detected uring 
operation. The patients who received long-term 
support were trained to manage their own power 
supply: they were able to change and recharge 
batteries and prepare for out-of-hospital walks on 
their own. Pump noise was not a problem for the 
Fig. 5. Photograph showing explanted inflow bovine peri- 
cardial valve prosthesis after 52 days of implantation. 
Distal side reveals areas of thrombotic deposits (arrow). 
patients. Development of the wearable system was a 
major step forward in providing mobility for patients 
in need of long-term support and improved quality 
of life during the waiting period. 
Thromboembolism remains the major threat dur- 
ing mechanical circulatory support. A reason for the 
thromboembolic event in one patient was the nor- 
malization of platelet function in the absence of 
acetylsalicylic a id or dipyridamole treatment during 
a period of low pump output (<3.5 L/min) caused 
by hypovolemia. Because a triple drug therapy con- 
sisting of heparin (intravenously or subcutaneously), 
acetylsalicylic acid, and dipyridamole has been used 
in the most recent wo patients, no more thrombo- 
embolic complications have been experienced. Some 
fibrinous depositions on the prosthetic inflow valve 
have been frequently observed. Multiple factors in- 
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cluding coagulation state, flow, and thrombotic depo- 
sition within the prosthetic device or native heart may 
contribute to thromboembolic complications. 
The question as to whether a patient who has a 
residual deficit after a cerebrovascular event should 
receive transplantation before complete rehabilita- 
tion may be an issue. However, after 10 to 14 days, 
patients hould be able to undergo cardiopulmonary 
bypass with minimal risk. 
In summary, hemodynamic and metabolic recom- 
pensation of patients who receive the Novacor 
LVAS is possible within a relatively short period of 
support. Postoperative anticoagulation is important 
to minimize the risk of thromboembolic complica- 
tions. Early mobilization and physical activities are 
easier to do in patients with use of the wearable 
system. 
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Discuss ion 
Dr. Eric A. Rose (New York, N.Y.). I congratulate you 
on these results and your illustration of the concept 
originally proposed by Bob Frazier and Victor Poirier that 
a vented system that is not totally implantable allows a 
reasonable quality of life in these patients. 
I have two questions. One is the issue of antieoagula- 
tion. I think it still remains peculative that the addition of 
antiplatelet agents to the already vigorous antieoagulation 
regimen that you described will be effective in preventing 
thromboembolism in these patients. 
Second, is the incidence of thromboembolism with the 
Novacor device low enough to consider the use of this 
type of device for long-term support? 
Dr. Vetter. I did not want to give the impression that 
adding anti-platelet aggregation medication will prevent 
thromboembolism. In the two patients who had a cere- 
brovascular ccident there were additional negative influ- 
ences present. In one patient here was, as a result of 
hypovolemia,  rather low pump output situation that 
might have contributed to the appearance of thrombus 
formation at the inflow valve. The other patient was in 
atrial fibrillation at the time of the cerebrovascular acci- 
dent. 
Another patient was supported by the device for 122 
days and received triple drug therapy (heparin intrave- 
nously, acetylsalicylic acid, and dipyridamole). He went 
through bridging without hromboembolism. Therefore I 
think that the Novacor LVAS in its present design is a 
suitable device for patients who need long-term support. 
Whether it is a device to send patients home with, I do not 
know yet. I think monitoring problems have to be solved 
in the future. 
Dr. Mortimer J. Buckley (Boston, Mass.). May I ask 
how you handled the right ventricular failure? In the 
Novacor LVAS, as I understand it, you cannot put in a 
biventricular system. 
Dr. Vetter. As I showed, our first four patients used the 
system only for a short term. The reason for that was in 
three of these patients there was poor right ventricular 
function. Right ventricular ejection fraction was 4%. We 
always wanted to manage without institution of a right 
ventricular support system because at that time we did not 
have the Berlin Heart (Berlin Heart, Fehling Medical, 
Berlin, Germany), and we did not have heparinized 
circuits for the Bio-Medicus pump (Bio-Medicus, Inc., 
Eden Prairie, Minn.). We would rather use medications, 
such as prostacycline, to improve postoperatively function 
of the right side of the heart. Therefore in these patients 
we went on with transplantation. One can see, however, 
timing is important for such patients, and we showed that 
a short time of bridging does not mean the outcome must 
be bad. 
